Matrix metalloproteinases

被引：249

作者：

Johnson, LL ^{[1
]}

Dyer, R ^{[1
]}

Hupe, DJ ^{[1
]}

机构：

[1] Warner Lambert Co, Parke Davis Pharmaceut Res, Dept Biochem, Ann Arbor, MI 48105 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 1998年 / 2卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(98)80122-1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Matrix metalloproteinases are a family of highly regulated peptidases that are collectively responsible for the degradation of extracellular matrix during tissue remodeling. Dysregulated activity has long been implicated in the pathologies of cancer and arthritis, and the number of diseases more recently associated with these enzymes has been increasing. In the past year, new transgenic models of matrix metalloproteinase knockouts have been described, allowing the direct assessment of specific enzyme activity in particular disease models. In addition, more selective inhibitors with improved pharmacokinetic profiles have entered clinical trials, allowing the assessment of the safety and efficacy of this strategy.

引用

页码：466 / 471

页数：6

共 52 条

[1] Matrix metalloproteinase inhibitors 1998 [J].

Beckett, RP ;

Whittaker, M .

EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (03) :259-282

[2] Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 [J].

Brooks, PC ;

Stromblad, S ;

Sanders, LC ;

vonSchalscha, TL ;

Aimes, RT ;

StetlerStevenson, WG ;

Quigley, JP ;

Cheresh, DA .

CELL, 1996, 85 (05) :683-693

[3] MATRILYSIN-INHIBITOR COMPLEXES - COMMON THEMES AMONG METALLOPROTEASES [J].

BROWNER, MF ;

SMITH, WW ;

CASTELHANO, AL .

BIOCHEMISTRY, 1995, 34 (20) :6602-6610

[4] Metalloproteinase inhibitors and the prevention of connective tissue breakdown [J].

Cawston, TE .

PHARMACOLOGY & THERAPEUTICS, 1996, 70 (03) :163-182

[5] Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview [J].

Chandler, S ;

Miller, KM ;

Clements, JM ;

Lury, J ;

Corkill, D ;

Anthony, DCC ;

Adams, SE ;

Gearing, AJH .

JOURNAL OF NEUROIMMUNOLOGY, 1997, 72 (02) :155-161

[6] Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor [J].

Clements, JM ;

Cossins, JA ;

Wells, GMA ;

Corkill, DJ ;

Helfrich, K ;

Wood, LM ;

Pigott, R ;

Stabler, G ;

Ward, GA ;

Gearing, AJH ;

Miller, KM .

JOURNAL OF NEUROIMMUNOLOGY, 1997, 74 (1-2) :85-94

[7] X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily [J].

Dhanaraj, V ;

Ye, QZ ;

Johnson, LL ;

Hupe, DJ ;

Ortwine, DF ;

Dubar, JB ;

Rubin, JR ;

Pavlovsky, A ;

Humblet, C ;

Blundell, TL .

STRUCTURE, 1996, 4 (04) :375-386

[8] MATRIX METALLOPROTEINASES AND CARDIOVASCULAR-DISEASE [J].

DOLLERY, CM ;

MCEWAN, JR ;

HENNEY, AM .

CIRCULATION RESEARCH, 1995, 77 (05) :863-868

[9] Influence of hypercholesterolemia and adventitial inflammation on the development of aortic aneurysm in rabbits [J].

Freestone, T ;

Turner, RJ ;

Higman, DJ ;

Lever, MJ ;

Powell, JT .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (01) :10-17

[10] REVERSAL OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS WITH A HYDROXAMATE INHIBITOR OF MATRIX METALLOPROTEASES [J].

GIJBELS, K ;

GALARDY, RE ;

STEINMAN, L .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (06) :2177-2182

← 1 2 3 4 5 6 →